Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis

University of Jena1 site in 1 country5 target enrollmentDecember 2005

ConditionsCystic Fibrosis Chronic Rhinosinusitis

InterventionsPulmozyme

DrugsPulmozyme

Overview

Phase: Phase 3
Intervention: Pulmozyme
Conditions: Cystic Fibrosis
Sponsor: University of Jena
Enrollment: 5
Locations: 1
Primary Endpoint: Changes in sinonasal symptoms (SNOT-20
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a dysfunction of Chloride channels in exocrine glands, leading to retention of secretions and consecutive chronic inflammation with bacterial superinfections.

The prospective placebo controlled cross-over study aims at the evaluation of the efficacy of a nasally inhalation of Pulmozyme with respect to mucus retention and resulting inflammation.

Registry

clinicaltrials.gov

Start Date

December 2005

End Date

May 2006

Last Updated

11 years ago

Study Type

Interventional

Study Design

Crossover